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Abstract
Background: Recent studies have suggested a role for an altered intestinal microbiota in the pathophysiology of
irritable bowel syndrome (IBS). However, no consensus has been reached regarding the association between
specific enteric bacterial groups and IBS. The aim of this study was to investigate the fecal and mucosal-associated
microbiota using two independent techniques in intestinal samples from diarrhea-predominant IBS (D-IBS) and
healthy controls.
Methods: Fecal and colonic mucosal biopsy samples were obtained from 10 D-IBS patients and 10 healthy
controls. Colonic tissue was collected during a un-sedated un-prepped flexible sigmoidoscopy. Fecal and tissue
samples were processed immediately upon collection for culture under aerobic and anaerobic conditions or frozen
for further molecular analysis. DNA was extracted from all frozen samples and used to enumerate specific bacterial
groups using quantitative real-time PCR (qPCR).
Results: Culture analysis of intestinal samples demonstrated a significant reduction in the concentration of aerobic
bacteria in fecal samples from D-IBS patients when compared to healthy controls (1.4 × 107 vs. 8.4 × 108 CFUs/g
feces, P = 0.002). qPCR analysis demonstrated a significant 3.6 fold increase (P = 0.02) in concentrations of fecal
Lactobacillus species between D-IBS patients and healthy controls.
Conclusions: Our culture and molecular data indicate that quantitative differences exist in specific bacterial groups
in the microbiota between D-IBS and healthy subjects.
Background
Functional gastrointestinal disorders (FGID) are highly
prevalent in Western countries with Irritable Bowel
Syndrome (IBS) being the most common (affecting
10-20% of adults and adolescents) [1] and best studied
condition. IBS is a heterogeneous disorder that can pre-
sent as diarrhea-predominant IBS (D-IBS), constipation-
predominant IBS (C-IBS), or mixed bowel habit IBS
(M-IBS) subsets. Traditionally IBS has been considered
a disorder that arises from an altered brain-gut axis that
can be associated with gastrointestinal (GI) hypersensi-
tivity and GI motor dysfunction[2,3]. Despite intensive
research, the pathophysiology of this disorder is still
unclear and no single etiological factor with a defined
pathogenic mechanism has been identified. However,
studies have implicated new theories that associate spe-
cific etiological factors in the pathogenesis of this disor-
der. These factors include alterations in the normal
intestinal microbiota, genetic pre-determinants, patho-
genic bacterial infection, food allergy, and an altered gut
immune function and inflammation[4-6].
The intestinal microbiota is a complex community of
bacteria, archaea, and eukarya. Indirect evidence that the
intestinal microbiota plays a role in IBS comes from epi-
demiologic studies identifying acute GI infection (e.g.,
acute gastroenteritis) as a strong predictor for the devel-
opment of IBS[7,8]. Additionally, antibiotic treatment of
small intestinal bacterial overgrowth (SIBO) is associated
with a resolution of IBS symptoms[9-11]. To further
understand the role of the intestinal microbiota in the
pathophysiology of IBS several studies have characterized
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this complex microbial community in IBS patients. Early
studies using selective and non-selective culture techni-
ques demonstrated differing viable levels of coliforms,
Lactobacillus, Bifidobacteria and Enterobacteriaceae spe-
cies in fecal samples from IBS patients[12,13]. More
recent studies have used molecular methods to character-
ize an abnormality or dysbiosis in the intestinal micro-
biota of IBS subjects and demonstrated variations in the
levels of the Eubacterium-Clostridium coccoides group
and Lactobacillus, Veillonella, Coprococcus, Collinsella,
Coprobacillus species in individuals with this disorder
[14-21]. However, the majority of these studies used
different, often mixed, patient populations and focused
their analysis on one specific intestinal niche (fecal
[12,16,17,20,21] or mucosal-associated[18] microbiota)
with only one study investigating both niches[14]. As the
luminal and mucosal-associated microbiota differs in
composition[22], it is important to investigate and com-
pare the microbiota of both of these niches.
In the present study we used two independent techni-
ques to quantify and compare specific bacterial groups in
fecal and colonic mucosal biopsy samples (collected in a
manner that accurately maintained the composition of the
microbiota) from patients with D-IBS and healthy controls.
Results
I. Study Population
A total of 20 subjects (10 D-IBS and 10 healthy con-
trols) were investigated. All subjects provided fecal and
colonic mucosal samples. The study population con-
sisted of 70% females and had a mean age of 32 years.
Demographics and body mass index (BMI) were similar
in the two study groups (Table 1).
II. Analysis of the fecal microbiota
The levels of aerobic bacteria in fecal samples from
D-IBS patients were significantly lower compared to
those from healthy controls (1.4 × 107 vs. 8.4 × 108
CFUs/g feces, P = 0.002) (Table 2). No significant differ-
ences were observed in the levels of anaerobic bacteria in
fecal samples from D-IBS patients and healthy controls
(6.24 × 109 vs. 3.12 × 109 CFUs/g feces, P = 0.3) (Table
2). Additionally, no significant differences between D-IBS
patients and healthy controls were detected using selec-
tive media for Bacteroides, Clostridium, Bifidobacteria,
Lactobacillus species and Escherichia coli concentrations
in fecal samples (Table 2).
qPCR analysis detected the concentration of Clostri-
dium, Bacteroides, Bifidobacterium, Lactobacillus spe-
cies, and E. coli in all fecal DNA samples with the
exception of 1 D-IBS samples that failed to amplify Lac-
tobacillus species sequences. A significant 3.6 fold
increase in the concentration of Lactobacillus species in
fecal samples from D-IBS patients was observed when
compared to healthy controls (HC = 10; D-IBS = 9, P =
0.02) (Figure 1E). No significant differences between
groups were observed for concentrations of Clostridium,
Bacteroides, Bifidobacterium species, and E. coli
(Figure 1A-D). Investigation of bacterial groups using
additional fecal samples from an on-going study (HC =
7, D-IBS = 6) using the same collection methods but
alternative fecal DNA isolation and qPCR methods
demonstrated similar results with a significant 2.7 fold
increase in Lactobacillus species in D-IBS fecal samples
compared to healthy controls (HC = 17; D-IBS = 15,
P = 0.02) (Figure 2). Similarly, no significant differences
between the groups in Clostridium, Bacteroides, Bifido-
bacterium species, and E. coli concentrations were
detected between healthy controls and D-IBS patients.
III. Analysis of the mucosal-associated intestinal
microbiota
No significant differences were observed in the levels of
aerobic or anaerobic bacteria in colonic mucosal samples
between D-IBS patients and healthy controls (Table 2).
Additionally, no significant differences between D-IBS
and healthy controls were detected using culture on
selective media for Bacteroides, Clostridium, Bifidobac-
teria, Lactobacillus species and Escherichia coli (Table 2).
qPCR analysis of colonic mucosal DNA did not reveal
any significant differences between groups for Clostri-
dium, Bacteroides, Bifidobacterium, and Lactobacillus
species and Escherichia coli (Figure 3A-E).
IV. Comparison of the fecal and mucosal-associated
microbiota
Comparison of the fecal and mucosal-associated micro-
biota in healthy control and D-IBS groups revealed a signif-
icantly lower level of cultivable aerobic bacteria in colonic
mucosal samples compared to fecal samples in both
groups. However, the differences in cultivable aerobic bac-
teria observed between colonic mucosal and fecal samples
from D-IBS patients was less obvious (Table 3). Both
healthy control and D-IBS groups displayed a significant
difference in cultivable anaerobes, Bacteroides, Clostridium,
Bifidobacteria species and E. coli between mucosal and
fecal niches (Table 3). These analyses could not be carried
out on Lactobacillus species as the levels of these organ-
isms were below detection limits in mucosal samples.
Table 1 Characteristics of D-IBS patients and Healthy
Controls
D-IBS patients Healthy Controls
Number of subjects 10 10
Age (yr): mean (range) 31.9 (23-50) 32.4 (21-54)
Gender: F/M 8/2 6/4
BMI (kg/m2): mean (range) 28.5 (23.1-40.6) 27.2 (19.9-36.3)
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Discussion
Recent studies have highlighted the importance of the
intestinal microbiota in the well-being of the host. This
diverse microbial community has been demonstrated as
a critical factor for normal GI function[3,23,24]. As
altered intestinal function is associated with IBS it is
possible that an intestinal dysbiosis plays a role in the
pathophysiology of the disorder. However, the investiga-
tion of the intestinal microbiota in IBS is difficult due to
the heterogeneity of this condition, and the effects of an
altered intestinal microbiota may not be consistent across
all subtypes of IBS (D-IBS, C-IBS and M-IBS). In addi-
tion, the relative importance of the luminal versus the
mucosal-associated niches in this disorder is not yet
clear. Nevertheless, many of the studies that sought to
characterize the intestinal microbiota in IBS investigated
mixed populations of IBS patients[12,13,18], or focused
on a single intestinal niche[12,13,15-21]. Thus, the aim of
Table 2 Culture analysis of fecal and colonic mucosal samples from D-IBS patients and healthy controls
Aerobic* Anaerobic* Clostridium spp.* Bacteroides spp.* Lactobacillus spp.* Bifidobacterium spp.* E. coli*
Fecal samples:
D-IBS patients 1.4 × 107 6.2 × 109 2.0 × 109 8.6 × 108 8.7 × 105 1.1 × 109 7.4 × 106
Healthy controls 8.4 × 108 3.1 × 109 6.0 × 108 3.5 × 108 8.7 × 107 6.4 × 108 1.4 × 108
P value¥ 0.002 0.14 0.11 0.07 0.08 0.43 0.13
Mucosal samples:
D-IBS patients 2.2 × 106 9.3 × 106 9.7 × 105 4.6 × 106 -§ 1.3 × 106 1.1 × 106
Healthy controls 4.8 × 105 6.5 × 106 1.9 × 106 1.4 × 106 -§ 5.9 × 105 7.5 × 103
P value¥ 0.96 0.85 0.36 0.78 - 0.68 0.44
*Concentrations expressed in CFUs/g of sample.
§ Below detection levels.
¥ P value calculated using the non-parametric Mann-Whitney test.
Figure 1 Fold change in concentrations of (A) Bacteroides species, (B) Bifidobacterium species, (C) Clostridium species, (D) E. coli, and
(E) Lactobacillus species in fecal samples from D-IBS patients and healthy controls using qPCR. A significant increase in the levels of
Lactobacillus species was detected in fecal samples from D-IBS patients (** P = 0.02).
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our study was to quantify and compare specific bacterial
groups in both the luminal and mucosal-associated
intestinal microbiota in a well-defined subgroup of
patients with IBS and healthy controls. To achieve this
we took the following measures; (a) we investigated a
defined IBS subgroup population (D-IBS) to avoid varia-
tion in the microbiota compositions between different
subtypes of IBS, (b) we used two independent techniques;
culture on selective and non-selective media and qPCR,
and (c) to avoid possible effects of time between delivery
and analysis on the luminal microbiota, fresh fecal sam-
ples were collected from study subjects on site. These
samples were immediately analyzed by culture or frozen
for molecular analysis. To avoid the effect of bowel pre-
paration on the mucosal-associated microbiota, colonic
mucosal samples were collected from patients that did
not receive a bowel preparation prior to the procedure.
The meticulous measures used in our study may explain
some of the differences between our study results and
previously reported studies investigating the intestinal
microbiota in patients with IBS. For example, using non-
selective culturing methods we found a decrease in con-
centrations of aerobic bacteria in D-IBS patients when
compared to healthy controls. Additionally, using selective
culture media we found no significant differences in
Figure 3 Fold change in concentrations of (A) Bacteroides species, (B) Bifidobacterium species, (C) Clostridium species, (D) E. coli, and
(E) Lactobacillus species in colonic mucosal samples from D-IBS patients and healthy controls using qPCR.
Figure 2 Fold change in concentrations of Lactobacillus species
in fecal samples from D-IBS patients and healthy controls
using a larger sample number and alternative DNA isolation
and qPCR methods. A significant increase in the levels of
Lactobacillus species was detected in fecal samples from D-IBS
patients (** P = 0.02).
Carroll et al. Gut Pathogens 2010, 2:19
http://www.gutpathogens.com/content/2/1/19
Page 4 of 9
concentrations of Clostridium, Bacteroides, Bifidobacter-
ium, and Lactobacillus species or E. coli between D-IBS
patients and healthy controls. These observations differ
from those of previous studies that used culture techni-
ques, where an increase in the total number of aerobic
bacteria and a decrease in coliforms, Lactobacillus and
Bifidobacterium species between IBS patients and healthy
controls was reported[12,13,17]. However, these studies
investigated a mixed population of IBS patients. In addi-
tion, one report investigated a population that included
more than 50% of hospitalized patients[12], which may be
a completely different population than the IBS population
investigated in our study. It is appreciated that enumera-
tion of specific bacterial groups using selective culture can
be inaccurate and allow for organisms other than the spe-
cies of interest to grow on a selective agar plate. Thus, the
alternative and more accurate method of qPCR was used
to enumerate different bacterial species in our samples.
Using qPCR our investigation demonstrated a signifi-
cant increase in the levels of Lactobacillus species in
fecal samples from D-IBS patients. As this finding was
not a priori anticipated and contradict a previous study
that reported a decrease in Lactobacillus species in
D-IBS patients[16], we validated our results by reanalyz-
ing our samples using alternate DNA extraction and
qPCR methods on a larger set of fecal samples. Repeat-
ing the analysis using larger numbers and different
methods yielded similar results of a significant increase
in Lactobacillus species in the fecal samples from
patients with D-IBS. Furthermore, our findings are sup-
ported by a study that demonstrated an increase in Lacto-
bacillus species in IBS subjects (a mixed subtype
population) using selective culturing techniques[19]. The
differing reported results may be a reflection of the differ-
ent ways of collecting samples as well as the alternate
fecal DNA extraction and qPCR methods used. In our
study we initially used a method that solely relied upon a
high temperature to lyse bacterial cells. As this method
may have a bias for bacteria with weaker cell walls (e.g.
Gram negative bacteria) we utilized an independent
method that ensures complete lysis of bacterial cells with
enzymatic (lysozyme and proteinase K), chemical
(sodium dodecyl sulfate), and physical disruption (bead-
beating) steps. Additionally, we incorporated a universal
bacterial primer set in our qPCR assay. The advantage of
using this approach is that the bacterial group under
investigation is determined as a percentage of total 16S
rRNA genes in a sample. In addition, the differences in
the reported results may relate to the differences in the
study population since the reported decrease in Lactoba-
cillus species was observed when comparing D-IBS and
C-IBS, but not compared to healthy controls[16].
Our analysis also compared different bacterial groups
harbored within fecal and mucosal niches of the intes-
tine. We observed that in healthy individuals and D-IBS
subjects the total number of cultivatable aerobic bacteria
significantly differed between the microbiota located at
these two intestinal sites. However, in D-IBS patients
the difference in the levels of aerobic bacteria found
between fecal and mucosal niches was less evident.
Interestingly, an opposite trend was observed in cultiva-
ble Bacteroides species, where a significant decrease in
the levels of this bacterial group was more obvious
between mucosal and fecal niches in D-IBS patients
than healthy controls. The remaining bacterial groups
investigated showed similar trends between mucosal and
fecal niches in both D-IBS patients and healthy controls.
At this point it is not known which anaerobic bacteria
or Bacteroides species are associated with these differ-
ences in intestinal niches between healthy individuals
and D-IBS patients. However, these observations war-
rant further examination.
To date two studies have investigated the microbiota of
luminal and mucosal niches within the intestine of IBS
subjects[14,25]. However, the first of these studies did
not collect mucosal samples from healthy controls[14].
In the second study, fecal and duodenal mucosa brush
samples were collected from IBS subjects and healthy
Table 3 Comparison of viable bacterial groups between fecal and colonic mucosal samples
Aerobic* Anaerobic* Clostridium spp.* Bacteroides spp.* Lactobacillus spp.* Bifidobacterium spp.* E. coli*
Healthy controls:
Feces 8.4 × 108 3.1 × 109 6.0 × 108 3.5 × 108 8.7 × 107 6.4 × 108 1.4 × 108
Mucosa 4.8 × 105 6.5 × 106 1.9 × 106 1.4 × 106 -§ 5.9 × 105 7.5 × 103
P value¥ 0.0003 0.0001 0.02 0.004 - 0.04 0.019
D-IBS patients:
Feces 1.4 × 107 6.2 × 109 2.0 × 109 8.6 × 108 8.7 × 105 1.1 × 109 7.4 × 106
Mucosa 2.2 × 106 9.3 × 106 9.7 × 105 4.6 × 106 -§ 1.3 × 106 1.1 × 106
P value¥ 0.05 0.0001 0.0001 0.0001 - 0.0001 0.01
*Concentrations expressed in CFUs/g of sample.
§Below detection levels.
¥P value calculated using the non-parametric Mann-Whitney test.
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controls[25]. Our study differed to these previous reports
as we collected fecal and colonic mucosal samples from
D-IBS subjects and healthy controls. Together our study
and these previous reports highlight the importance of
investigating both luminal and mucosal niches in the
intestine of IBS subjects and healthy controls.
Conclusions
Our data demonstrate differences in both the luminal and
mucosal-associated intestinal microbiota between patients
with D-IBS and healthy controls. These data suggest that
both fecal and mucosal intestinal niches may indepen-
dently have an important association with D-IBS. The clin-
ical relevance of these observations still need to be
addressed as it is difficult to establish whether differences
in the intestinal microbiota between D-IBS patients and
healthy controls are a cause of the disorder or an effect of
the altered intestinal function or luminal environment in
these patients. It is also appreciated that this study focused
on a limited number of clinically relevant bacterial species
in a small sample of patients and does not provide a gen-
eralized view of the diverse intestinal microbiota. However,
our study presents interesting new findings that substanti-
ates further in depth investigation of the fecal and muco-
sal-associated intestinal microbiota in IBS and sub-types
of IBS using methods that characterize the composition of
the intestinal microbiota in greater details.
Methods
Study Population
We studied 10 patients that met the Rome III criteria
for D-IBS and 10 healthy controls[1]. Subjects were
recruited from the Chapel Hill general population by
advertising and from the University of North Carolina
(UNC) at Chapel Hill outpatient clinics.
Inclusion criteria comprised of subjects at least 18
years of age and of any gender, race, or ethnicity. All
subjects were evaluated by a physician to exclude an
alternative diagnosis to IBS. D-IBS subjects had active
GI symptoms at the time of sample collection. Healthy
controls had no significant recurring GI symptoms. Sub-
jects with a history of GI tract surgery other than
appendectomy or cholecystectomy, a history of inflam-
matory bowel diseases (IBD), celiac disease, lactose
malabsorption, or any other diagnosis that could explain
chronic or recurring bowel symptoms were excluded
from the study. In addition, participants were excluded
if they had a history of antibiotic treatment or inten-
tional probiotic consumption two months prior to the
beginning of the study.
The extra subjects used to validate qPCR analysis (HC
= 7, D-IBS = 6) were recruited in the same manner. The
study was approved by the UNC Internal Review Board
(IRB) and all subjects signed a consent form prior to
participation in the study.
Sample Collection and Preparation
Fresh stool samples were collected from all 20 subjects
on site during the study visit at UNC. Each fecal sample
was immediately placed in an anaerobic pouch system
(AnaeroPack® System, Misubishi Gas Chemical America,
Inc.) and transferred on ice to the laboratory. In the
laboratory, each stool sample was homogenized and
divided into aliquots. Samples were immediately used
for culture of viable bacteria and the remaining aliquots
were stored at -80°C for DNA extraction and qPCR ana-
lysis. The extra 13 subjects included to validate our ana-
lyses (HC = 7, D-IBS = 6) provided a fecal sample
which processed in the same manner for DNA extrac-
tion and qPCR analysis.
Three colonic mucosal biopsies were collected from
each subject during an un-sedated flexible sigmoidoscopy.
To avoid possible effects of colonic preparation on the
intestinal microbiota all the procedures were carried out
on un-prepped colons. Colonic mucosal biopsies were
taken from the distal colon just above the rectosigmoid
junction using cold forceps. Once removed from the colon
each biopsy was washed in 1 ml of sterile PBS to remove
non-adherent bacteria. The biopsies were then weighed
and used immediately for culture of viable bacteria while
other samples were flash-frozen in liquid nitrogen for
further DNA extraction and qPCR analysis.
Culture of Fecal and Mucosal Microorganisms
An aliquot of a fresh fecal sample or colonic biopsy was
aseptically added to sterile phosphate buffer saline (PBS) to
obtain a final volume of 1 ml. Fecal samples were vortexed
until a homogenous suspension was obtained and colonic
biopsies were vortexed for 2 min to ensure the release of
all adherent bacteria. The mixture was then serially diluted
and spread onto appropriate selective and non-selective
agar plates for the detection of specific bacterial groups by
aerobic and anaerobic culture. The concentrations of each
bacterial group were expressed as the number of colony
forming units (CFUs) per gram of sample. The following
types of micro-organisms were enumerated:
Total Bacterial Counts
Total aerobic and anaerobic numbers were determined
by culturing diluted samples on Brain Heart Infusion
(BHI) agar plates (Difico™, Franklin Lakes, NJ) supple-
mented with L-cystine (0.05%) and hemin (5 mg L-1).
Agar plates were incubated aerobically at 37°C for 24 hr
to enumerate total aerobic bacteria or anaerobically
(10% H2, 80% N2, and 10% CO2) for 48 hr to enumerate
total anaerobic bacteria. All colonies encompassing dif-
ferent morphologies were counted on these plates.
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Bifidobacteria species
Columbia agar base plates (Difico™, Franklin Lakes, NJ)
supplemented with L-cystine (0.05%), hemin (5 mg L-1),
horse blood (5%), and a bile salt solution (bile salts:
Sodium propionate - 4.5 g L-1, paromonycin sulphate -
15 g L-1, Neomycin sulfate - 60 g L-1and Lithium chlor-
ide - 900 mg g L-1) were used to culture and enumerate
Bifidobacteria species. All incubations were carried out
anaerobically at 37°C.
Lactobacillus species
Man, Rogosa, and Sharpe (MRS) agar plates (Difico™,
Franklin Lakes, NJ) supplemented with L-cystine (0.05%)
and hemin (5 mg L-1) were used to enumerate Lactoba-
cillus species. All incubations were carried out anaerobi-
cally at 37°C.
Escherichia coli
McConkey agar (Difico™, Franklin Lakes, NJ) was used
to enumerate E. coli. All incubations were carried out
aerobically at 37°C.
Clostridium species
McClung Toabe agar plates (Difico™, Franklin Lakes, NJ)
were used to enumerate total Clostridium species. All
incubations were carried out anaerobically at 37°C.
Bacteroides species
Bacteroides Bile Esculin agar plates (Difico™, Franklin
Lakes, NJ) were used to enumerate Bacteroides species.
All plates were incubated anaerobically at 37°C.
Extraction of Fecal DNA
Fecal Samples
Fecal DNA was extracted using the QIAamp® DNA stool
mini kit (Qiagen, Valencia, CA). Briefly, 200 mg was
taken from each frozen stool sample and placed imme-
diately into ASL buffer. Each fecal sample was homoge-
nized by vortexing. The mixture was then heated to
95°C for 5 min to obtain bacterial lysis. Fecal DNA was
further extracted and purified as per the manufacturer’s
instructions. DNA concentrations were determined
using a NanoDrop™ (Thermo Scientific, Wilmington,
DE). All fecal DNA samples were adjusted to equal con-
centrations for subsequent qPCR analysis.
To validate our molecular observations an alternate
DNA extraction method was applied to all fecal samples
with the addition of 13 extra stool specimens (HC = 7,
D-IBS = 6) from an ongoing study (total sample number,
HC = 17, D-IBS = 16). This method used more rigorous
steps to lyse bacterial cell walls. Briefly, DNA from fecal
samples was extracted using a phenol/chloroform extrac-
tion method combined with physical disruption of bacter-
ial cells and a DNA clean-up kit (Qiagen DNeasy® Blood
and Tissue extraction kit). 100 mg of frozen feces was sus-
pended in 750 μl of sterile bacterial lysis buffer (200 mM
NaCl, 100 mM Tris [pH 8.0], 20 mM EDTA, 20 mg/ml
lysozyme [Sigma-Aldrich, St. Louis, MO]) and incubated
at 37°C for 30 min. Next, 40 μl of proteinase K (20 mg/ml)
and 85 μl of 10% SDS was added to the mixture and incu-
bated at 65°C for 30 min. 300 mg of 0.1 mm zirconium
beads (BioSpec Products, Bartlesville, OK) was then added
and the mixture and homogenized in a bead beater (BioS-
pec Products, Bartlesville, OK) for 2 min. The homoge-
nized mixture was cooled on ice and then centrifuged at
14,000 rpm for 5 min. The supernatant was transferred to
a new 1.5 ml microfuge tube and fecal DNA was further
extracted by phenol/chloroform/iso-amyl alcohol (25:24:1)
and then chloroform/iso-amyl alcohol (24:1). The super-
natant after extraction was precipitated by absolute etha-
nol at -20°C for 1 hour. The precipitated DNA was
suspended in DNase free H2O and then cleaned using the
DNeasy® Blood and Tissue extraction kit (Qiagen) from
step 3 as per the manufacturer’s instructions.
Table 4 Quantitative polymerase chain reaction (qPCR) primes used in this study to enumerate specific bacterial
species
Bacterial species Primer Sequence 5’-3’ Annealing temperature (°C) PCR Product size (bp)
Bacteroides spp.a F-
R-
ATAGCCTTTCGAAAGRAAGAT
CCAGTATCAACTGCAATTTTA
50 495
Clostridium spp.b F-
R-
CGGTACCTGACTAAGAAGC
AGTTTYATTCTTGCGAACG
50 429
Escherichia colic F-
R-
GTTAATACCTTTGCTCATTGA
ACCAGGGTATCTAATCCTGTT
52 340
Bifidobacterium spp.d F-
R-
GGGTGGTAATGCCGGATG
TAAGCGATGGACTTTCACACC
55 442
Lactobacillus spp.e F-
R-
AGCAGTAGGGAATCTTCCA
CACCGCTACACATGGAG
50 341
aprimers from Matsuki et al.,[26]
bprimers from Rinttila et al.,[27]
cprimers from Malinen et al.,[28]
dprimers from Bartoch et al.,[29]
eprimers from Maeda et al.,[30]
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Mucosal Samples
DNA from colonic mucosal biopsies was extracted using
the Qiagen Allprep DNA/RNA kit™ (Qiagen, Valencia,
CA) with the addition of a lysozyme and bead-beating
step. Briefly, each biopsy was incubated in 300 μl of a
lysozyme solution (30 mg/ml) for 30 min at 37°C. Next,
600 μl of RLT buffer (containing b-mercaptoethanol)
and 300 mg of 0.1 mm zirconium beads (BioSpec Pro-
ducts, Bartlesville, OK) were added and the solution was
homogenized in a bead beater (BioSpec Products,
Bartlesville, OK) for 2 min. The solution was centrifuged
for 5 min at 14,000 rpm and DNA was further extracted
from the supernatant as per the manufacturer’s
instructions.
Quantitative PCR
Quantitative PCR (qPCR) was performed using the
QuantiTect SYBR® Green PCR kit (Qiagen, Valencia,
CA) with primers that amplify the genes encoding 16S
rRNA from specific bacterial groups. The primers used
to amplify specific groups of are listed in Table 4. qPCR
assays were conducted in 96-well plates on a real-time
MX 3000P thermocycler (Stratagene, La Jolla, CA). Each
PCR was carried out in a final volume of 25 μl and con-
tained the following: 1 × SYBR green qPCR Master Mix
(Qiagen), 0.5 μM of each primer and 50 ng of purified
fecal or colonic mucosal DNA. PCR conditions were as
follows: 15 min at 95°C, followed by 40 cycles of 95°C
for 1 min, 30 s at the appropriate annealing temperature
(Table 4), and 72°C for 1 min. Each plate included
duplicate reactions per DNA sample and the appropriate
set of standards. qPCR standards were generated by
PCR amplifying and cloning the target 16S rRNA genes
from an appropriate positive control strain. Melting
curve analysis of the PCR products was conducted fol-
lowing each assay to confirm that the fluorescence sig-
nal originated from specific PCR products and not from
primer-dimers or other artifacts. All qPCR plates
included a ‘no template’ negative control for each pri-
mer set. The concentrations of each bacterial group in
D-IBS patients were expressed as a ‘fold change’ with
respect to the control group. All microbiology analyses
of fecal and colonic mucosal samples were performed
blindly, without knowledge of the subjects’ clinical data.
To validate our qPCR findings an alternate qPCR
method was applied to our larger number of fecal DNA
samples (HC = 17, D-IBS = 16). Briefly, qPCR was per-
formed using ABI SYBR® Green PCR Mastermix
(Applied Biosystems, Carlsbad, CA) with primers that
amplify the genes encoding 16S rRNA from Lactobacil-
lus species (Table 4) or all bacteria (total bacterial 16S
rRNA in each sample was determined using universal
16S rRNA primers; forward, 5’-GTGSTGCAYG
GYTGTCGTCA-3’; reverse, 5’-ACGTCRTCCMCACCT
TCCTC-3’) in fecal DNA from D-IBS patients and
healthy controls. qPCR assays were conducted in 96-
well plates on an Eppendorf Realplex2 mastercycler ther-
mocycler (Eppendorf, Hauppauge, NY). Each PCR was
carried out in a final volume of 12 μl and contained the
following: 1 × SYBR green mastermix, 0.5 μM of each
primer and approximately 50 ng of purified fecal DNA.
PCR conditions were as follows: 15 min at 95°C, fol-
lowed by 40 cycles of 95°C for 15 s, 30 s at the appro-
priate annealing temperature (Table 4), and 72°C for
45 s. Each plate included duplicate reactions per DNA
sample and the appropriate set of standards. The con-
centration of Lactobacillus species were expressed as a
percentage of total 16S rRNA sequences in a given sam-
ple. Analysis of melting curves confirmed that the fluor-
escence signal originated from specific PCR products
and not from primer-dimers or other artifacts. All qPCR
plates included a ‘no template’ negative control for each
primer set. The concentrations of each bacterial group
in D-IBS patients were expressed as a ‘fold change’ with
respect to the control group.
Statistical Analysis
For culture analysis the total number of CFUs per gram
of feces for aerobic, anaerobic, and each specific bacter-
ial species investigated was determined for each sample.
Mean total aerobic, anaerobic and species specific CFUs
were compared between D-IBS patients and healthy
controls using the non-parametric Mann-Whitney test.
Similarly, for qPCR assays the concentration of each
bacterium/bacterial group was determined for each sam-
ple. Mean number of 16S rRNA sequences per μg of
sample DNA was compared between D-IBS patients and
healthy controls using the non-parametric Mann-Whitney
test. Statistical analysis was carried out using GraphPad
software (v4.0a; Prism, San Diego, CA).
List of Abbreviations
IBS: irritable bowel syndrome; D/C/M-IBS: diarrhea/constipation/mixed bowel
habit-predominant IBS; HC: healthy controls; CFU: colony forming units;
qPCR: quantitative real-time PCR; FGID: functional gastrointestinal disorders;
SIBO: small intestinal bacterial overgrowth.
Acknowledgements and Funding
The authors would like to acknowledge Sarah Van Heusen and Sarah Yeskel
for their valuable contributions to this study. This study was funded by a
DK067674 seed grant from the UNC Center for Functional GI Disorders
awarded to YR.
Author details
1Division of Gastroenterology and Hepatology, Center for Gastrointestinal
Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina, USA. 2Korea Research Institute of Bioscience and
Biotechnology (KRIBB), Dagjon, Korea.
Authors’ contributions
IMC - molecular techniques, statistical analysis, and scribe of manuscript.
YHC - collection of biological samples and culture techniques.
Carroll et al. Gut Pathogens 2010, 2:19
http://www.gutpathogens.com/content/2/1/19
Page 8 of 9
JP - culture techniques.
RBS - study design.
YR - study design, study execution, recruitment of subjects, IRB application
scribe, and recipient of funding for study.
All authors read and approved the final draft.
Competing interests
The authors declare that they have no competing interests.
Received: 1 November 2010 Accepted: 9 December 2010
Published: 9 December 2010
References
1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F,
Spiller RC: Functional bowel disorders. Gastroenterology 2006,
130(5):1480-1491.
2. Drossman DA: The functional gastrointestinal disorders and the Rome III
process. Gastroenterology 2006, 130(5):1377-1390.
3. Ringel Y, Carroll IM: Alterations in the intestinal microbiota and functional
bowel symptoms. Gastrointest Endosc Clin N Am 2009, 19(1):141-150, vii.
4. Ringel Y, Sperber AD, Drossman DA: Irritable bowel syndrome. Annu Rev
Med 2001, 52:319-338.
5. Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, Spiller RC:
Mechanisms of hypersensitivity in IBS and functional disorders.
Neurogastroenterol Motil 2007, 19(1 Suppl):62-88.
6. Scanu AM, Bull TJ, Cannas S, Sanderson JD, Sechi LA, Dettori G, Zanetti S,
Hermon-Taylor J: Mycobacterium avium subspecies paratuberculosis
infection in cases of irritable bowel syndrome and comparison with
Crohn’s disease and Johne’s disease: common neural and immune
pathogenicities. J Clin Microbiol 2007, 45(12):3883-3890.
7. Rodriguez LA, Ruigomez A: Increased risk of irritable bowel syndrome
after bacterial gastroenteritis: cohort study. Bmj 1999, 318(7183):565-566.
8. Spiller RC: Is IBS caused by infectious diarrhea? Nat Clin Pract
Gastroenterol Hepatol. 2007, 4(12):642-643.
9. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing
correlates with symptom improvement in irritable bowel syndrome. a
double-blind, randomized, placebo-controlled study. Am J Gastroenterol
2003, 98(2):412-419.
10. Pimentel M: Review of rifaximin as treatment for SIBO and IBS. Expert
Opin Investig Drugs 2009, 18(3):349-358.
11. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial
overgrowth reduces symptoms of irritable bowel syndrome. Am J
Gastroenterol 2000, 95(12):3503-3506.
12. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G: The fecal microbial
population in the irritable bowel syndrome. Microbiologica 1982,
5(3):185-194.
13. Si JM, Yu YC, Fan YJ, Chen SJ: Intestinal microecology and quality of life
in irritable bowel syndrome patients. World J Gastroenterol 2004,
10(12):1802-1805.
14. Codling C, O’Mahony L, Shanahan F, Quigley EM, Marchesi JR: A Molecular
Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel
Syndrome. Dig Dis Sci 2010, 55(2):392-397.
15. Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J,
Malinen E, Apajalahti J, Palva A: The fecal microbiota of irritable bowel
syndrome patients differs significantly from that of healthy subjects.
Gastroenterology 2007, 133(1):24-33.
16. Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, Saarela M,
Korpela R, Palva A: Analysis of the fecal microbiota of irritable bowel
syndrome patients and healthy controls with real-time PCR. Am J
Gastroenterol 2005, 100(2):373-382.
17. Matto J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M:
Composition and temporal stability of gastrointestinal microbiota in
irritable bowel syndrome–a longitudinal study in IBS and control
subjects. FEMS Immunol Med Microbiol 2005, 43(2):213-222.
18. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial
organization and composition of the mucosal flora in patients with
inflammatory bowel disease. J Clin Microbiol 2005, 43(7):3380-3389.
19. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S: Altered
profiles of intestinal microbiota and organic acids may be the origin of
symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010,
22(55):512-519.
20. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L,
Makivuokko H, Kajander K, Palva A: Microbial community analysis reveals
high level phylogenetic alterations in the overall gastrointestinal
microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.
BMC Gastroenterol 2009, 9:95.
21. Lyra A, Rinttila T, Nikkila J, Krogius-Kurikka L, Kajander K, Malinen E, Matto J,
Makela L, Palva A: Diarrhoea-predominant irritable bowel syndrome
distinguishable by 16S rRNA gene phylotype quantification. World J
Gastroenterol 2009, 15(47):5936-5945.
22. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K,
Akkermans AD, de Vos WM: Mucosa-associated bacteria in the human
gastrointestinal tract are uniformly distributed along the colon and
differ from the community recovered from feces. Appl Environ Microbiol
2002, 68(7):3401-3407.
23. Caenepeel P, Janssens J, Vantrappen G, Eyssen H, Coremans G:
Interdigestive myoelectric complex in germ-free rats. Dig Dis Sci 1989,
34(8):1180-1184.
24. Husebye E, Hellstrom PM, Sundler F, Chen J, Midtvedt T: Influence of
microbial species on small intestinal myoelectric activity and transit in
germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001, 280(3):G368-380.
25. Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K,
Akkermans LM: Lower Bifidobacteria counts in both duodenal mucosa-
associated and fecal microbiota in irritable bowel syndrome patients.
World J Gastroenterol 2009, 15(23):2887-2892.
26. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R: Use of 16S rRNA gene-
targeted group-specific primers for real-time PCR analysis of predominant
bacteria in human feces. Appl Environ Microbiol 2004, 70(12):7220-7228.
27. Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A: Development of an
extensive set of 16S rDNA-targeted primers for quantification of
pathogenic and indigenous bacteria in faecal samples by real-time PCR.
J Appl Microbiol 2004, 97(6):1166-1177.
28. Malinen E, Kassinen A, Rinttila T, Palva A: Comparison of real-time PCR
with SYBR Green I or 5’-nuclease assays and dot-blot hybridization with
rDNA-targeted oligonucleotide probes in quantification of selected
faecal bacteria. Microbiology 2003, 149(Pt 1):269-277.
29. Bartosch S, Fite A, Macfarlane GT, McMurdo ME: Characterization of
bacterial communities in feces from healthy elderly volunteers and
hospitalized elderly patients by using real-time PCR and effects of
antibiotic treatment on the fecal microbiota. Appl Environ Microbiol 2004,
70(6):3575-3581.
30. Maeda H, Fujimoto C, Haruki Y, Maeda T, Kokeguchi S, Petelin M, Arai H,
Tanimoto I, Nishimura F, Takashiba S: Quantitative real-time PCR using
TaqMan and SYBR Green for Actinobacillus actinomycetemcomitans,
Porphyromonas gingivalis, Prevotella intermedia, tetQ gene and total
bacteria. FEMS Immunol Med Microbiol 2003, 39(1):81-86.
doi:10.1186/1757-4749-2-19
Cite this article as: Carroll et al.: Luminal and mucosal-associated
intestinal microbiota in patients with diarrhea-predominant irritable
bowel syndrome. Gut Pathogens 2010 2:19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Carroll et al. Gut Pathogens 2010, 2:19
http://www.gutpathogens.com/content/2/1/19
Page 9 of 9
